Lincoln Capital LLC Buys 10,387 Shares of Danaher Corporation $DHR

Key Points

• Lincoln Capital LLC increased its stake in Danaher Corporation by 13.6%, now holding 86,653 shares valued at approximately $16.6 million, making it the firm's 6th largest position.
• Several institutional investors, including Vanguard Group Inc. and Invesco Ltd., have also increased their holdings in Danaher, contributing to a total of 79.05% of the stock owned by institutional investors.
• Analysts have set a new average target price for Danaher at $247.61, with a majority rating it as a "Moderate Buy" despite some price target reductions by firms like JPMorgan and Goldman Sachs.

Lincoln Capital LLC lifted its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 13.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 86,653 shares of the conglomerate's stock after purchasing an additional 10,387 shares during the quarter. Danaher accounts for 3.4% of Lincoln Capital LLC's portfolio, making the stock its 6th largest position. Lincoln Capital LLC's holdings in Danaher were worth $16,643,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of Danaher by 0.4% during the first quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate's stock worth $12,296,123,000 after acquiring an additional 230,966 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of Danaher by 2.3% during the first quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock worth $1,800,614,000 after buying an additional 194,466 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Danaher by 14.3% during the fourth quarter. Northern Trust Corp now owns 7,934,991 shares of the conglomerate's stock worth $1,821,477,000 after buying an additional 992,594 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Danaher by 11.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,677,032 shares of the conglomerate's stock worth $1,303,163,000 after buying an additional 579,046 shares in the last quarter. Finally, Invesco Ltd. grew its holdings in shares of Danaher by 44.5% during the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock worth $965,259,000 after buying an additional 1,450,703 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. JPMorgan Chase & Co. decreased their price objective on Danaher from $280.00 to $260.00 and set an "overweight" rating for the company in a report on Tuesday, April 22nd. The Goldman Sachs Group lowered their price target on shares of Danaher from $260.00 to $240.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 23rd. Robert W. Baird lifted their price target on shares of Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a research note on Friday, July 18th. Scotiabank upgraded shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price target on the stock in a research note on Friday, July 11th. Finally, HSBC lowered their price target on shares of Danaher from $270.00 to $240.00 in a research note on Friday, April 25th. Three research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company's stock. According to data from MarketBeat, Danaher presently has an average rating of "Moderate Buy" and an average target price of $247.61.

Danaher Stock Up 0.3%

DHR opened at $210.84 on Monday. The company has a market cap of $150.97 billion, a P/E ratio of 44.86, a P/E/G ratio of 2.94 and a beta of 0.73. The business's 50-day moving average price is $199.94 and its 200-day moving average price is $199.54. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $279.90.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.64 by $0.16. The business had revenue of $5.94 billion for the quarter, compared to analysts' expectations of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%. The business's revenue was up 3.4% on a year-over-year basis. During the same period in the previous year, the firm posted $1.72 EPS. On average, equities analysts expect that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.